It is made available under a CC-BY-NC-ND 4.0 International license .

1 Title

- 2 U-shaped-aggressiveness of SARS-CoV-2: Period between initial symptoms and clinical progression to COVID-19
- 3 suspicion. A population-based cohort study

4 Short Title

5 U-shaped aggressiveness of SARS-CoV-2

6 Authors

- 7 Dan Morgenstern-Kaplan¹[¶], Bruno Buitano-Tang^{1¶}, Mercedes Martínez-Gil^{1&}, Andrea Zaldívar-Pérez Pavón^{1&},
- 8 Juan O. Talavera $^{1,2^*}$.

9 Affiliations

- 10 1. Centro de Investigación en Ciencias de la Salud Anáhuac (CICSA), Facultad de Ciencias de la Salud,
- 11 Universidad Anáhuac México, Huixquilucan, Estado de México, México
- 12 2. Department of Medical Education and Research, ABC Medical Center, Mexico City, CDMX, Mexico.
- 13 *Corresponding Author
- 14 E-mail: jotalaverap@abchospital.com,
- 15 [¶] These authors contributed equally to this work.
- [&] These authors also contributed equally to this work.

- 18
- 19
- 20
- 21

It is made available under a CC-BY-NC-ND 4.0 International license .

22 Abstract

- 23 Background: Early identification of different COVID-19 clinical presentations may depict distinct
- 24 pathophysiological mechanisms and guide management strategies.
- 25 **Objective:** To determine the aggressiveness of SARS-CoV-2 using symptom progression in COVID-19 patients.
- 26 Design: Historic cohort study of Mexican patients. Data from January-April 2020 were provided by the Health
- 27 Ministry.
- 28 Setting: Population-based. Patients registered in the Epidemiologic Surveillance System in Mexico.
- 29 Participants: Subjects who sought medical attention for clinical suspicion of COVID-19. All patients were
- 30 subjected to RT-PCR testing for SARS-CoV-2.
- 31 Measurements: We measured the Period between initial symptoms and clinical progression to COVID-19 suspicion
- 32 (PISYCS) and compared it to the primary outcomes (mortality and pneumonia).
- **Results:** 65,500 patients were included. Reported fatalities and pneumonia were 2176 (3.32%), and 11568
- 34 (17.66%), respectively. According to the PISYCS, patients were distributed as follows: 14.89% in <24 hours,
- 35 43.25% between 1-3 days, 31.87% between 4-7 days and 9.97% >7 days. The distribution for mortality and
- 36 pneumonia was 5.2% and 22.5% in <24 hours, 2.5% and 14% between 1-3 days, 3.6% and 19.5% between 4-7 days,
- 4.1% and 20.6% >7 days, respectively (p<0.001). Adjusted-risk of mortality was (OR [95% CI], p-value): <24
- 38 hours= 1.75 [1.55-1.98], p<0.001; 1-3 days= 1 (reference value); 4-7 days= 1.53 [1.37-1.70], p<0.001; >7 days=
- 39 1.67 [1.44-1.94], p<0.001. For pneumonia: <24 hours= 1.49 [1.39-1.58], p<0.001; 1-3 days= 1; 4-7 days= 1.48
- 40 [1.41-1.56], p<0.001; >7 days= 1.57 [1.46-1.69], p<0.001.
- 41 Limitations: Using a database fed by large numbers of people carries the risk of data inaccuracy. However, this
- 42 imprecision is expected to be random and data are consistent with previous studies.
- 43 Conclusion: The PISYCS shows a U-shaped SARS-CoV-2 aggressiveness pattern. Further studies are needed to
- 44 corroborate the time-related pathophysiology behind these findings.
- 45
- 46 Key Words: COVID-19, Epidemiology, Public Health, Pandemic, Mortality

It is made available under a CC-BY-NC-ND 4.0 International license .

48 Introduction

49 50 Coronaviruses are single-stranded RNA organisms capable of infecting humans and other animal species [1,2]. The 51 most recently discovered coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), is cause 52 of the clinical entity denominated Coronavirus Disease 2019 (COVID-19). This virus initially spread in the Wuhan 53 province in China and later to the rest of the world, causing a pandemic [3]. Reported worldwide cases are 54 continuously growing and currently (as of July 3rd, 2020) there are over 10 million infected people confirmed and 55 over 500,000 fatalities. Global reports reveal case-fatality rate of 4.8% and more than half of the cases are in the 56 Americas region. In Mexico, over 230,000 cases have been reported, with over 28,000 fatalities and a case-fatality 57 rate of 12.3%, which by far surpasses the global estimate [4]. 58 Every human in the world is susceptible to infection, for as the mean age of infected patients is 47 years, 87% of 59 patients lie between 30 and 79 years old. COVID-19 behaves more aggressively in older patients and in patients 60 undergoing chronic medical conditions such as obesity, diabetes [5,6], hypertension and other cardiovascular 61 diseases, increasing the risk of mortality in these populations [7,8]. Approximately 80% of cases are asymptomatic 62 with a mild disease course, while the other 20% can be accompanied of severe complications such as pneumonia, 63 Acute Respiratory Distress Syndrome (ARDS) and other secondary infections. Among these severe cases, 80% 64 correspond to people over 60 years. Many of these cases can be attributed to a severe clinical entity known as 65 "cytokine storm", which causes a rise in serum levels of many pro-inflammatory mediators and provokes massive 66 tissue damage in several vital organs [7,9]. 67 In patients who developed severe symptoms, dyspnea was reported between 8-12 days after onset of symptoms, and 68 some patients deteriorate into severe disease during the first week after onset of symptoms. This accelerated 69 worsening has been hypothesized to be caused by the cytokine storm and to thrombotic events that may be caused 70 by infection with SARS-CoV-2 [10]. 71 Hospitalized patients have been thoroughly described and analyzed, with an average time between onset of 72 symptoms to intubation of 14.5 days, and a time from intubation to death ranging from 4-5 days [7,9,11]. A longer 73 period between onset of symptoms and first contact seeking medical attention has been associated with a poorer 74 outcome in these patients. However no in-depth studies have been conducted [12]. 75 Until now, studies have been focused on patient-centered risk factors, while SARS-CoV-2 aggressiveness has been

restablished as provoking 20% of severe and critic patients [13], however, there are still many unanswered questions

It is made available under a CC-BY-NC-ND 4.0 International license .

- 77 concerning the clinical aggressiveness behavior of SARS-CoV-2. This study focuses on progression of symptoms as
- a marker of such aggressiveness, using the Period between initial symptoms and clinical progression to COVID-19
- suspicion (PISYCS) to determine the risk of severe disease and mortality.
- 80

81 Methods

82 Study Design and Data Source

A historic cohort study of Mexican patients that were classified as a suspect case of COVID-19 and sought medical attention in either public or private health services in Mexico, was analyzed. Data was provided by the General Directorate of Epidemiology of the Mexican Health Ministry, which is deidentified, publicly available online, and registers all patients in the Epidemiologic Surveillance System of the 32 federal states in Mexico. This analysis was done in all cases registered in this dataset up until April 25th, 2020, with a total of 65,500 patients [14]. The Institutional Review Board of Anahuac University (Mexico City, Mexico) approved this study (Protocol approval #202044).

90

91 Variable Definition

92 Our dataset includes demographic characteristics such as age, gender, location, health sector, underlying medical

93 conditions (obesity, diabetes, COPD, asthma, immunosuppression, hypertension, cardiovascular, chronic kidney

94 diseases, and other comorbid diseases), pregnancy status, tobacco use, and indigenous language speaker.

95 Furthermore, it references the dates of the onset of symptoms and the date of medical attention, including hospital

96 admission, as well as the presence of pneumonia. Regarding in-hospital decisions, data include results of RT-PCR

97 testing for SARS-CoV-2 (reported as positive, negative or pending), admission to the Intensive Care Unit (ICU) and

98 requirement of mechanical ventilation. Finally, the date of death of all deceased patients is reported.

99

100 Data Analysis: Coding and substitution of variables

101 The state where the patient sought attention was recoded according to the socio-economic level of that particular

102 state into low, middle and high level, based on the Gross Domestic Product (GDP) of that state, as reported by the

It is made available under a CC-BY-NC-ND 4.0 International license .

- 103 National Institute of Statistics and Geography (INEGI) [15]. The health sector variable was recoded in three
- 104 categories: private, with social security and without social security.
- 105 COVID-19 clinical suspicion was defined by the government health ministry's official guidelines, as presenting with
- 106 two of these symptoms: 1) cough, 2) fever or 3) headache, plus one or more of the following: 1) breathing difficulty,
- 107 2) sore or burning throat, 3) runny nose, 4) red eyes, 5) pain in muscles or joints, or 6) being part of these high-risk
- 108 groups: pregnancy, <5 or ≥60 years old, or having a chronic disease such as hypertension, diabetes mellitus, cancer
- 109 or HIV.
- 110 These indications were broadcast on television, radio, newspaper and internet platforms since the beginning of the
- 111 pandemic until July 1, 2020. Due to nationwide government issued stay-at-home orders, we assumed that medical
- 112 attention was sought only when these criteria were met.
- 113 Upon medical evaluation, patients were asked to report the date of onset of initial symptoms (any combination of
- 114 clinical features that appeared before meeting the previously mentioned criteria). Therefore, the Period between
- 115 initial symptoms and clinical progression to COVID-19 suspicion (PISYCS) was established as the number of days
- 116 between appearance of initial symptoms and the date in which the patients sought medical attention.
- 117 PISYCS
- 118 Initially, PISYCS was categorized in days (<1, 1, 2, 3, etc.), but to improve comprehension and data management,
- adjacent days whose frequency of death remained in similar proportions, were grouped into 4 categories (<24 hours,
- 120 1-3 days, 4-7 days and >7 days). The primary outcomes were mortality and pneumonia. The presence of pneumonia
- 121 was used as an indicator of severe disease as reported in previous studies [7,9].
- 122 Missing data were substituted using the mode for the following categorical variables: Health Sector (338 patients,
- 123 0.5%), indigenous language speaker (1241, 2%), tobacco use (242, 0.4%), pregnancy status (166, 0.3%), diabetes
- 124 (255, 0.4%), COPD (245, 0.4%), asthma (251, 0.4%), immunosuppression (259, 0.4%), hypertension (241, 0.4%),
- 125 cardiovascular disease (252, 0.4%), obesity (220, 0.3%), chronic kidney disease (245, 0.4%), other comorbid
- 126 condition (331, 0.5%), admission to the ICU (12, <0.01%) and mechanical ventilation (12, <0.01%).
- 127

128 Statistical Analysis

- 129 Demographic features and comorbid conditions were initially compared between the four categories of PISYCS; age
- 130 was analyzed with a one-way ANOVA and the rest of the variables with Chi squared test analysis. Afterwards, we

It is made available under a CC-BY-NC-ND 4.0 International license .

- 131 performed a bivariate analysis comparing the four categories of PISYCS with the medical decisions made (result of
- 132 PCR testing for SARS-CoV-2, hospital admission, ICU, mechanical ventilation) and outcomes (mortality and
- 133 pneumonia) using the Chi squared test.
- 134 Finally, the four categories of PISYCS against primary outcomes -mortality and pneumonia-, were compared using a
- 135 multivariable logistic regression model. The model was adjusted in five steps for the following variables: age,
- 136 gender, indigenous language speaker, state's socioeconomic status, pregnancy, tobacco use, obesity, hypertension,
- 137 diabetes, asthma, COPD, cardiovascular disease, chronic kidney disease, immunosuppression, other comorbid
- 138 conditions. This model was repeated in four groups of patients within the sample, depending on their RT-PCR
- 139 testing result for SARS-CoV-2:
- a. All patients: Every patient in the dataset regardless of their test result
- b. Positives: Only patients with a positive test result
- 142 c. Negatives: Only patients with a negative test result
- 143 d. Pending: Only patients with pending results of the test
- 144 The PISYCS used as reference in the regression models, was 1-3 days based in the lower rate of mortality, observed
- 145 in the results of the bivariate analysis. Each logistic regression model is presented with the Odds Ratio (OR) and its
- 146 respective 95% Confidence Interval (CI_{95%}). Statistical significance was set at p<0.05 and performed with SPSS
- 147 version 25.0 (IBM). The full model for the group of all patients can be found in the Supporting Information Section.
- 148

149 **Results**

- 150 The study population included 65,500 patients. Among them, the average age was 41±17 years, 50.2%, were
- 151 women, 55.8% belonged to a high socioeconomic level, 27.7% to a medium and 16.5% to a low one, 4.6% of
- patients were treated on a private health institution, 37.7% in a facility for patients with social security and 57.7%
- 153 attended to a public hospital for patients without social security. Of all the patients, 41% had at least one
- 154 comorbidity, hypertension being the most frequent in 17%, followed by obesity in 15.6% and diabetes 12.8%. In
- addition, 9.9% reported tobacco use and 2.3% of women were pregnant. Mortality was observed in 2176 patients
- 156 (3.32%), and Pneumonia in 11568 patients (17.66%).

It is made available under a CC-BY-NC-ND 4.0 International license .

Period between initial symptoms and clinical progression to COVID-19	Global P
suspicion (PISYCS)	Value

- According to PISYCS patients were distributed as follows: 14.89% in <24 hours, 43.25% between 1-3 days, 31.87%
- between 4-7 days and 9.97% after 7 days, with no significant difference by gender. We compared PISYCS against
- demographic features and comorbidities. A PISYCS of <24 hours was more frequent in older patients (25.7% in
- 160 patients > 80 years old vs. 15% in < 30 years old) reversing in the period of 1-3 days (41.5% vs 48.4%),
- 161 respectively), and returning to the initial behavior in subsequent periods. This same pattern was observed when
- 162 comparing PISYCS with the presence of all comorbidities, except for asthma and obesity. Demographic
- 163 Characteristics of all patients are summarized in Table 1.
- 164

165Table 1. Patient demographic characteristics according to Period between initial symptoms and

166 clinical progression to COVID-19 suspicion (PISYCS)

It is made available under a CC-BY-NC-ND 4.0 International license .

		<24	4 Hrs	1-3 Days		4-7 Days		>7 Days			
		(n=	9759)	(n=2	8331)	(n=2	20877)	(n=	=6533)		
	·	N	%	N	%	N	%	N	%		
Gender	Female	4686	14.3%	14371	43.7%	10562	32.1%	3260	9.9%	<0.001	
	Male	5073	15.6%	13960	42.8%	10315	31.6%	3273	10.0%		
	< 30	2469	15.0%	7965	48.4%	4732	28.7%	1302	7.9%		
	30-49	3745	12.8%	12813	43.6%	9785	33.3%	3016	10.3%		
	50-59	1430	14.7%	3875	39.7%	3321	34.1%	1123	11.5%	<0.001	
Age	60-69	1095	19.8%	2006	36.2%	1785	32.2%	656	11.8%		
	70-79	615	21.9%	1018	36.3%	863	30.7%	311	11.1%		
	> 80	405	25.7%	654	41.5%	391	24.8%	125	7.9%		
	Mean (SD)	43	(20) [*]	40	(18)	42	(17)**	44	(16)***	<0.001	
State's	High	5532	15.1%	15745	43.1%	11352	31.1%	3921	10.7%		
Socioeconomic	Medium	2878	15.8%	8027	44.2%	5868	32.3%	1402	7.7%	<0.001	
Status	Low	1349	12.5%	4559	42.3%	3657	33.9%	1210	11.2%		
	Private	468	15.6%	1228	40.9%	885	29.5%	418	13.9%		
Health Sector	With SS	4584	18.6%	10515	42.6%	7274	29.5%	2321	9.4%	<0.001	
	Without SS	4707	12.5%	16588	43.9%	12718	33.6%	3794	10.0%		
Indigenous	Yes	98	14.4%	277	40.8%	242	35.6%	62	9.1%	0.20	
Language Speaker	No	9661	14.9%	28054	43.4%	20635	31.8%	6471	10.0%	0.20	
Prograncy	Yes	139	18.3%	383	50.5%	190	25.1% ^{**}	46	6.1%***	<0.001	
Tregnancy	No	9620	14.9%	27948	43.2%	20687	32.0%	6487	10.0%		
Tobacco Use	Yes	946	14.5%	2786	42.8%	2122	32.6%	661	10.1%	0 / 0	
	No	8813	14.9%	25545	43.3%	18755	31.8%	5872	10.0%	0.49	
Diabotos	Yes	1514	18.1% [*]	3307	39.5%	2684	32.1% ^{**}	867	10.4%***	<0.001	
Diabetes	No	8245	14.4%	25024	43.8%	18193	31.8%	5666	9.9%	\0.001	
COPD	Yes	401	22.6% [*]	685	38.6%	535	30.2%	153	8.6%	<0.001	
	No	9358	14.7%	27646	43.4%	20342	31.9%	6380	10.0%	~0.001	
Asthma	Yes	394	12.4% [*]	1422	44.6%	1034	32.5%	336	10.5%	0.001	
Astima	No	9365	15.0%	26909	43.2%	19843	31.8%	6197	9.9%	0.001	
Immunosuppression	Yes	455	26.1%	697	40.0%	429	24.6%	163	9.3%	<0.001	
	No	9304	14.6%	27634	43.3%	20448	32.1%	6370	10.0%	\0.001	
Hypertension	Yes	1932	17.4% [*]	4415	39.7%	3593	32.3%	1194	10.7%	<0.001	
	No	7827	14.4%	23916	44.0%	17284	31.8%	5339	9.8%		
Cardiovascular	Yes	470	22.0%	820	38.3%	627	29.3%	224	10.5%	<0.001	
Disease	No	9289	14.7%	27511	43.4%	20250	32.0%	6309	10.0%		
Obesity	Yes	1381	13.5%	4093	40.0%	3633	35.5%	1119	10.9%	<0.001	
	No	8378	15.2%	24238	43.9%	17244	31.2%	5414	9.8%		
Chronic Kidney	Yes	435	28.1%	612	39.5%	374	24.1%	129	8.3%	<0.001	
Disease	No	9324	14.6%	27719	43.3%	20503	32.1%	6404	10.0%		
Other Comorbid	Yes	662	19.0%	1440	41.3%	1059	30.4%	323	9.3%	<0.001	
Condition	No	9097	14.7%	26891	43.4%	19818	32.0%	6210	10.0%	~0.001	

It is made available under a CC-BY-NC-ND 4.0 International license .

- 167 SS= Social Security. COPD=Chronic Obstructive Pulmonary Disease. SD=Standard Deviation. Statistical
- 168 Significance p<0.05, * Significant Difference between periods of <24 hrs. and 1-3 days. ** Significant Difference
- 169 between periods of 4-7 days and 1-3 days.^{***} Significant Difference between periods of >7 days and 1-3 days.
- 170
- 171 Table 2 shows the initial medical decisions according to their PISYCS. More people were hospitalized in the first 24
- hours (43.2%), with a drop towards the period of 1-3 days (19.7%), and a slight increase in subsequent days. A
- 173 similar phenomenon is observed in terms of admission to the ICU, with admission being 2.8% when the period is
- 174 <24 hours, falling to 1.8% in 1-3 days, and gradually increasing to 2.7% in 4-7 days and 3.2% in >7 days. The
- 175 proportion of patients under mechanical ventilation steadily increased over time, starting from 1.6% in the period of
- 176 < 24 hours, up to 2.9% in the period of >7 days.
- 177

178 Table 2. Medical Decisions according Period between initial symptoms and clinical progression to COVID-19

179 suspicion (PISYCS).

Period between initial symptoms and clinical progression to suspicion (PISYCS)PISYCS						on to C	OVID-19			
		<24 Hrs (n=9759)		1-3 Days (n=28331)		4-7 Days (n=20877)		>7 Days (n=6533)		Global P Value
		Ν	%	Ν	%	Ν	%	Ν	%	
Type of care	Ambulatory Care	5547	56.8%*	22742	80.3%	15674	75.1%**	4837	74.0% ***	< 0.001
	Hospital Admission	4212	43.2%	5589	19.7%	5203	24.9%	1696	26.0%	
Admission to the ICU		271	$2.8\%^*$	503	1.8%	563	$2.7\%^{**}$	208	3.2% ***	< 0.001
Mechanical Ventilation		155	1.6%	479	1.7%	525	2.5%**	189	2.9% ***	< 0.001
Result of	Not Positive to SARS-CoV 2	7036	81.4%*	19801	80.4%	12672	69.8%**	3910	66.5% ***	<0.001
Test ⁺	Positive to SARS- CoV-2	1601	18.6%	4818	19.6%	5462	30.2%	1961	33.5%	<0.001

180 ICU= Intensive Care Unit. PCR= Polymerase Chain Reaction. SD= Standard Deviation

181 Statistical Significance p<0.05, *Significant Difference between periods of <24 hrs and 1-3 days. ** Significant

182 Difference between periods of 4-7 days and 1-3 days. *** Significant Difference between periods of >7 days and 1-3

183 *days.* ⁺ Undefined were not included.

- 184
- 185 Table 3 and Fig 1 show the risks for mortality and pneumonia related to PISYCS. A "U-shaped distribution" was
- 186 observed according to PISYCS (<24 hrs., followed by 1-3 days, 4-7, and >7). The proportion of patients with
- 187 Mortality was 5.2%, 2.5%, 3.6%, and 4.1% (p<0.001), and for Pneumonia 22.5%, 14%, 19.5% and 20.6%

It is made available under a CC-BY-NC-ND 4.0 International license .

- 188 (p<0.001). The adjusted-risk of mortality for all patients evaluated for clinical suspicion of COVID-19 according to
- 189 PISYCS, was for <24 hours OR of 1.75 (95% CI, 1.55 to 1.98, p = <0.001), 1-3 days OR = 1 (reference value), 4-7
- 190 days, OR 1.53 (1.37-1.70, $p = \langle 0.001 \rangle$, and \rangle 7 days, OR 1.67 (1.44-1.94, $p = \langle 0.001 \rangle$), while for Pneumonia it was
- 191 for <24 hours OR of 1.49 (95% CI, 1.39 to 1.58, p = <0.001), 1-3 days OR = 1 (reference value), 4-7 days, OR 1.48
- 192 (1.41-1.56, p = <0.001), and >7 days, OR 1.57 (1.46-1.69, p = <0.001).
- 193

194 Table 3. Mortality and Pneumonia among patients with COVID-19 according to the Period between initial

195 symptoms and clinical progression to COVID-19 suspicion (PISYCS).

Variable		Mortality		Pneumonia				
All Patients (N=65,500)	A ()		-	A (1		-		
PISYCS(N)	%*	OR (95% CI)	p-value	%* OR (95% CI		p-value		
< 24 Hours (9759)	5.2%	1.75 (1.55-1.98)	< 0.001	22.5%	1.49 (1.39-1.58)	< 0.001		
1-3 Days (28331)	2.5%	1	1	14%	1	1		
4-7 Days (20877)	3.6%	1.53 (1.37-1.70)	< 0.001	19.5	1.48 (1.41-1.56)	< 0.001		
> 7 Days (6533)	4.1%	1.67 (1.44-1.94)	< 0.001	20.6%	1.57 (1.46-1.69)	< 0.001		
"p value"	< 0.001			< 0.001				
		SUBGROUP A	NALYSIS					
Positive Test (N=13,842)								
PISYCS	0	R (95% CI)	p-value	O	R (95% CI)	p-value		
< 24 Hours	2.1	1 (1.75-2.55)	< 0.001	1.6	< 0.001			
1-3 Days		1	1		1			
4-7 Days	1.4	2 (1.22-1.65)	< 0.001	1.6	< 0.001			
> 7 Days	1.2	22 (1.00-1.49)	0.053	1.8	< 0.001			
Negative Test (N=43,419)								
PISYCS	0	R (95% CI)	p-value	O	R (95% CI)	p-value		
< 24 Hours	1.5	55 (1.29-1.86)	< 0.001	1.5	8 (1.46-1.70)	< 0.001		
1-3 Days		1	1		1	1		
4-7 Days	1.0	00 (0.83-1.21)	0.967	1.10	0.038			
> 7 Days	1.3	9 (1.10-1.81)	0.014	1.1	0.061			
Test Result Pending								
(N=8,239)								
PISYCS	0	R (95% CI)	p-value	O	R (95% CI)	p-value		
< 24 Hours	1.4	1 (0.68-2.90)	0.357	0.8	0 (0.64-0.99)	0.043		
1-3 Days		1	1	1		1		
4-7 Days	1.2	22 (0.70-2.13)	0.484	2.0	< 0.001			
> 7 Days	1.7	1 (0.78-3.74)	0.182	1.9	< 0.001			

196 This Global Multiple Logistic Regression Model is adjusted for all demographic characteristics and comorbid

197 conditions present in the patients. Adjustments for the group of all patients can be found in the Supporting

198 Information Section.

199 *Bivariate analysis between PISYCS vs. Mortality or Pneumonia.

200

201 Fig 1. U-Shaped Distribution of the odds ratio for the primary outcomes (mortality/pneumonia) vs. PISYCS.

It is made available under a CC-BY-NC-ND 4.0 International license .

- 202 Caption: Association according to the Period between initial symptoms and clinical progression to COVID-19
- suspicion (PISYCS) and the primary outcomes of the study (Mortality and Pneumonia), including all patients. A U-
- shaped distribution is observed, with higher OR for PISYCS <24 hours and \geq 4 days.
- 205
- 206

207 **Discussion**

- 208 In this study, we found an association concerning the Period between initial symptoms and clinical progression to
- 209 COVID-19 suspicion (PISYCS) with the risk of severe disease and mortality in patients with suspected COVID-19.
- 210 A "U shaped" distribution was observed, with a high risk of death and pneumonia when PISYCS is <24 hours (OR
- 211 1.75, and 1.49, respectively), with a decrease of this risk in 1-3 days (OR 1), and with an additional rise in
- 212 subsequent periods of 4-7 days (OR 1.53, and 1.48) and >7 days (OR 1.67 and 1.57).
- 213 The increased risk of mortality and pneumonia observed in patients with PISYCS <24 hours, may be associated with
- the presence of a cytokine storm, which has been previously described as an early factor for severity[16]. This
- 215 phenomenon is due to the uncontrolled release of pro-inflammatory mediators that lead to apoptosis of epithelial and
- 216 endothelial lung cells, causing vascular extravasation, alveolar edema and hypoxia [17] This inflammatory response
- 217 in conjunction with the production of reactive oxygen species triggers an acute respiratory distress syndrome
- 218 (ARDS) leading to pulmonary fibrosis and death[18]. This could support the pharmacodynamic basis for the use of
- corticosteroids as adjuvant therapy in patients with COVID-19, which has been reported in other studies [19].
- 220 Chronic use of inhaled corticosteroids may be the reason why asthmatic patients manifest less severe symptoms[20],
- 221 which was consistent with our results (See S1-S2 Tables).
- 222 The increased risk of mortality and pneumonia in patients with PISYCS \geq 4 days, could be explained by the
- thrombotic events that have been reported in patients with COVID-19. These events are caused by the excessive
- inflammation produced by the virus and platelet activation with accompanying endothelial damage[21,22]. This
- 225 occurs once the virus has colonized the respiratory system, impairing microvascular permeability, helping it spread
- even further. Hemostatic disorders are established by the presence of thrombocytopenia, and an increase in the D-
- dimer and fibrinogen, for which the use of antithrombotic therapies has been suggested[21,23].

It is made available under a CC-BY-NC-ND 4.0 International license .

Additionally, an increased risk of lung superinfections must be considered. So far, bacterial and fungal pneumonias

have been the most common etiologies. A study conducted in Wuhan, China reported a rate of lung superinfection

from 5-27% in adults with COVID-19 [24]. Historically, superinfections have been associated with increased

231 mortality in other viral respiratory infections, such as influenza [25].

232 Our findings may have further clinical implications if the pathophysiological processes were to be confirmed. The

233 PISYCS could be useful as a prognostic marker and a decision-making tool for clinicians. Identifying individuals at

higher risk of developing early-onset complications (with a PISYCS <24 hours) could justify a more aggressive

treatment plan and monitorization strategies, focused on preventing complications of cytokine storm and ARDS.

Additionally, patients with a higher risk of late-onset complications (with a PISYCS \geq 4 days) could be identified

and treated accordingly, justifying the use of thromboprophylaxis, preventing superinfections.

238 The PISYCS could also prove useful as a research categorization parameter for clinical studies exploring timing and

efficacy of therapeutics. Immunomodulatory agents (such as IL-6 antagonists) and corticosteroids may only prove

beneficial for patients with a PISYCS of < 24 hours and may further increase the risk of late-onset complications

241 (superinfections) if used in a later PISYCS category [24].

242

243 Using a database fed by large numbers of people carries its risk, such as data inaccuracy. However, this imprecision 244 is expected to be random and data are consistent with results of previous studies. Furthermore, we set April 25th, 245 2020 as our cut-off date with the aim of including patients treated at an early stage of the pandemic in Mexico, at a 246 time when hospitals were not yet working at overcapacity. This increases the probability of good quality of 247 healthcare, decreases confounding factors for the outcomes evaluated because all required medical decisions could 248 be made and were not limited by medical resources available at the time (i.e. number of ventilators or ICU beds). 249 Plenty of studies have described the incubation period and hospital stay of affected patients [7,26,27]. However, 250 nobody has considered the progression of symptoms in patients with COVID-19 (PISYCS), as a guide for 251 explaining the time-specific pathophysiology associated with the U-Shaped SARS-CoV-2 aggressiveness. Further 252 studies are needed to corroborate the time-related pathophysiology behind these findings. Eventually, this could help 253 identify specific therapies aimed towards the temporal progression of the disease. 254

It is made available under a CC-BY-NC-ND 4.0 International license .

256 Acknowledgments

- 257 The authors report no conflicts of interest regarding the present study. The Dataset used for all statistical analyses is
- available in the Mendeley Data Repository Online at: <u>http://dx.doi.org/10.17632/k6cw45366d.1</u>

259

It is made available under a CC-BY-NC-ND 4.0 International license .

261 **References**

262 1. Tyrrell DA, Bynoe ML. Cultivation of viruses from a high proportion of patients with colds. Lancet. 1966;1:

263 76–77. doi:10.1016/s0140-6736(66)92364-6

- 264 2. Velavan TP, Meyer CG. The COVID-19 epidemic. Trop Med Int Heal. 2020;25: 278–280.
- 265 doi:10.1111/tmi.13383
- 266 3. Battegay M, Kuehl R, Tschudin-Sutter S, Hirsch HH, Widmer AF, Neher RA. 2019-novel Coronavirus
- 267 (2019-nCoV): estimating the case fatality rate a word of caution. Swiss Med Wkly. 2020;150: w20203.

268 doi:10.4414/smw.2020.20203

- World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard. In: WHO [Internet]. 2020.
 Available: https://covid19.who.int/
- 271 5. Maddaloni E, D'Onofrio L, Alessandri F, Mignogna C, Leto G, Coraggio L, et al. Clinical features of
- patients with type 2 diabetes with and without Covid-19: A case control study (CoViDiab I). Diabetes Res
 Clin Pract. 2020;169: 1–7. doi:10.1016/j.diabres.2020.108454
- 6. Maddaloni E, D'Onofrio L, Alessandri F, Mignogna C, Leto G, Pascarella G, et al. Cardiometabolic
- 275 multimorbidity is associated with a worse Covid-19 prognosis than individual cardiometabolic risk factors:
- A multicentre retrospective study (CoViDiab II). Cardiovasc Diabetol. 2020;19: 1–11. doi:10.1186/s12933-
- 277 020-01140-2
- 278 7. Wang L, He W, Yu X, Hu D, Bao M, Liu H, et al. Coronavirus disease 2019 in elderly patients:
- 279 Characteristics and prognostic factors based on 4-week follow-up. J Infect. 2020.
- 280 doi:10.1016/j.jinf.2020.03.019
- 281 8. Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R. Features, Evaluation and Treatment
- 282 Coronavirus (COVID-19) StatPearls NCBI Bookshelf. StatPearls. 2020. pp. 1–17. Available:
- 283 https://www.ncbi.nlm.nih.gov/pubmed/32150360
- 284 9. Zhou P, Yang X Lou, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a
 285 new coronavirus of probable bat origin. Nature. 2020;579: 270–273. doi:10.1038/s41586-020-2012-7
- 286 10. Centers For Disease Control. Interim Clinical Guidance for Management of Patients with Confirmed
- 287 Coronavirus Disease (COVID-19). 2020. Available: https://www.cdc.gov/coronavirus/2019-

It is made available under a CC-BY-NC-ND 4.0 International license .

288		ncov/hcp/clinical-guidance-management-patients.html
289	11.	Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult
290		inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395: 1054–1062.
291		doi:10.1016/S0140-6736(20)30566-3
292	12.	Liang W, Guan W, Li C, Li Y, Liang H, Zhao Y, et al. Clinical characteristics and outcomes of hospitalised
293		patients with COVID-19 treated in Hubei (epicentre) and outside Hubei (non-epicentre): a nationwide
294		analysis of China. Eur Respir J. 2020;55: 2000562. doi:10.1183/13993003.00562-2020
295	13.	Azoulay E, Fartoukh M, Darmon M, Géri G, Voiriot G, Dupont T, et al. Increased mortality in patients with
296		severe SARS-CoV-2 infection admitted within seven days of disease onset. Intensive Care Med. 2020;46:
297		1714–1722. doi:10.1007/s00134-020-06202-3
298	14.	Direccion General de Epidemiologia, Secretaría de Salud. Datos Abiertos - Bases Históricas. 2020.
299		Available: https://www.gob.mx/salud/documentos/datos-abiertos-bases-historicas-direccion-general-de-
300		epidemiologia
301	15.	INEGI. Comunicado De Prensa Núm . 384 / 19 31 De Julio De 2019 El Inegi Da a Conocer Los Resultados
302		De La Encuesta Nacional De Ingresos Y Gastos De Los Hogares (Enigh) 2018. Comun prensa INEGI.
303		2019.
304	16.	Henderson LA, Canna SW, Schulert GS, Volpi S, Lee PY, Kernan KF, et al. On the alert for cytokine storm:
305		Immunopathology in COVID-19. Arthritis Rheumatol. 2020;72: 1059–1063. doi:10.1002/art.41285
306	17.	Pascarella G, Strumia A, Piliego C, Bruno F, Del Buono R, Costa F, et al. COVID-19 diagnosis and
307		management: a comprehensive review. J Intern Med. 2020;288: 192-206. doi:10.1111/joim.13091
308	18.	Sun X, Wang T, Cai D, Hu Z, Chen J, Liao H, et al. Cytokine storm intervention in the early stages of
309		COVID-19 pneumonia. Cytokine Growth Factor Rev. 2020;53: 38-42. doi:10.1016/j.cytogfr.2020.04.002
310	19.	Horby P, Lim WS, Emberson J, Mafham M, Bell J, Linsell L, et al. Effect of Dexamethasone in
311		Hospitalized Patients with COVID-19: Preliminary Report. medRxiv. 2020; 2020.06.22.20137273.
312		doi:10.1101/2020.06.22.20137273
313	20.	Liu S, Zhi Y, Ying S. COVID-19 and Asthma: Reflection During the Pandemic. Clin Rev Allergy Immunol.
314		2020. doi:10.1007/s12016-020-08797-3
315	21.	Bikdeli B, Madhavan M V., Jimenez D, Chuich T, Dreyfus I, Driggin E, et al. COVID-19 and Thrombotic

It is made available under a CC-BY-NC-ND 4.0 International license .

316		or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC
317		State-of-the-Art Review. J Am Coll Cardiol. 2020;75: 2950-2973. doi:10.1016/j.jacc.2020.04.031
318	22.	Cannegieter SC, Klok FA. COVID 19 associated coagulopathy and thromboembolic disease: Commentary
319		on an interim expert guidance. Res Pract Thromb Haemost. 2020;4: 439-445. doi:10.1002/rth2.12350
320	23.	Yuki K, Fujiogi M, Koutsogiannaki S. COVID-19 pathophysiology: A review. Clin Immunol. 2020;215.
321		doi:10.1016/j.clim.2020.108427
322	24.	Clancy CJ, Nguyen MH. Coronavirus Disease 2019, Superinfections, and Antimicrobial Development:
323		What Can We Expect? Clin Infect Dis. 2020. doi:10.1093/cid/ciaa524
324	25.	Rynda-Apple A, Robinson KM, Alcorn JF. Influenza and bacterial superinfection: Illuminating the
325		immunologic mechanisms of disease. Infect Immun. 2015;83: 3764-3770. doi:10.1128/IAI.00298-15
326	26.	Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, et al. The incubation period of coronavirus
327		disease 2019 (CoVID-19) from publicly reported confirmed cases: Estimation and application. Ann Intern
328		Med. 2020;172: 577-582. doi:10.7326/M20-0504
329	27.	Sun Q, Qiu H, Huang M, Yang Y. Lower mortality of COVID-19 by early recognition and intervention:
330		experience from Jiangsu Province. Ann Intensive Care. 2020;10: 2-5. doi:10.1186/s13613-020-00650-2
331		
332		
333 334 335 336 337 338 339 340		
341	Suj	pporting Information
342	S1 Ta	ble. Stepwise analyses for binary logistic regression with Mortality as outcome for all patients in the
343	study	
344	S2 Ta	ble. Stepwise analyses for binary logistic regression with Pneumonia as outcome for all patients in the
345	study	•

Figure 1. All Patients: PISYCS vs. Primary Outcomes (OR, 95% CI) 2 1.8 1.75 (1.55-1.98), p <.001 1.67 (1.44-1.94), p <.001 1.6 1.57 (1.46-1.69), p <.001 1.53 (1.37-1 70), p <.00 Odds Ratio (OR) 1.49 (1.39-1.58), p <.001 1.48 (1.41-1.56), p <.001 1.4 1.2 < 24 hrs 1-3 Days 4-7 Days > 7 Days 0.8